Blood Collection Tubes for Liquid Biopsy Market is expected to reach US$ 428.66 million by 2031

ccfDNA/cfDNA Tubes Under Product Segment to Bolster Blood Collection Tubes for Liquid Biopsy Market Size During 2023–2031

According to our new research study on "Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 – Global Analysis – by Product and End User," the market is expected to grow from US$ 110.13 million in 2023 to US$ 428.66 million by 2031; it is anticipated to record a CAGR of 18.5% from 2023 to 2031. The blood collection tubes for liquid biopsy market report emphasizes the trends prevalent in the global market, along with drivers and deterrents affecting its growth.

An increase in the prevalence of cancer worldwide and the advantages of liquid biopsy over other diagnostic testing techniques are among the most influential factors responsible for the blood collection tubes for liquid biopsy market growth. However, a lack of skilled professionals hinders the market growth. Technological advancements in liquid biopsy are expected to bring new blood collection tubes for liquid biopsy market trends in the coming years.

Blood Collection Tubes for Liquid Biopsy Market Share, by Region, 2023 (%)

Source: The Insight Partners Analysis

Increase in Prevalence of Cancer Propels Blood Collection Tubes for Liquid Biopsy Market Growth

Health systems across the world are witnessing an exponential increase in the prevalence of cancer. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the WHO, nearly 10 million deaths were caused by cancer in 2020 across the world. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, approximately 0.61 million people were anticipated to die in 2024 in the US due to cancer. According to data published by Macmillan Cancer Support, ~392,000 people in the UK are diagnosed with cancer every year, while ~167,000 people die due to the disease each year.

Early prognosis, tumor heterogeneity detection, reduced cost, and patient comfort are a few of the advantages of liquid biopsy over other cancer diagnostics approaches. Thus, the preference for liquid biopsy, allowing for quick treatment and enhancing cancer patients' survival rates, is increasing with the rise in cancer prevalence during the projection period. Blood collection tubes that are used in liquid biopsy play an instrumental role in the early and precise cancer detection strategies of various organizations. Thus, the increasing prevalence of cancer is contributing significantly to the growth of the blood collection tubes for liquid biopsy market.

Based on product, the blood collection tubes for liquid biopsy market is divided into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. The ccfDNA/cfDNA tubes segment held the largest market share in 2023. Human venous whole blood is drawn, stored, and transported using ccfDNA tubes. These tubes are also used to stabilize DNA to prepare genomic DNA (gDNA) from the nucleated cellular fraction and circulating cell-free DNA (ccfDNA) from plasma. Whole blood obtained in ccfDNA tubes is used to extract plasma. The ccfDNA kit is then used to process the blood either automatically or manually. Clinical laboratories can use the ccfDNA tubes to stabilize the samples when samples cannot be processed on the same day they are collected. Owing to the unique stabilization chemistry of ccfDNA tubes, collection and processing can take place days apart. Standard EDTA tubes, on the other hand, need to be processed within hours before the cells degenerate and release genomic DNA into the blood plasma, which modifies the original ccfDNA profile. Additives used in these tubes prevent the degradation of cfDNA, enabling precise analysis in diagnostic procedures such as cancer liquid biopsy and noninvasive prenatal testing (NIPT). They play a critical role in clinical settings where monitoring disease progression or detecting genetic abnormalities requires cfDNA analysis. Moreover, many molecular diagnostic companies are focused on creating new tests for patient screening and monitoring, especially for oncology applications. A safe, clinically acceptable system for blood collection and ccfDNA processing can be used to stabilize a sample for performing ccfDNA extraction after a sample is transported to a different location, which is not achievable with EDTA tubes. The accuracy of molecular diagnostic tests depends on minimizing the possibility of preanalytical errors. According to BD, a well-known international medical technology company, in February 2018, the PAXgene Blood ccfDNA tube with a CE-IVD mark became commercially available in the European Economic Area and Switzerland (Western Europe). The plastic blood collection tube was created to ensure accurate and reproducible results in molecular diagnostic testing applications using ccfDNA, such as cancer and noninvasive prenatal tests. It also includes a proprietary sample stabilization additive and BD Vacutainer Hemogard to help ensure healthcare worker safety. The product was developed by PreAnalytiX GmbH, a joint venture between BD and QIAGEN.

Based on material, the blood collection tubes for liquid biopsy market is divided into glass and plastic. The plastic segment held a larger market share in 2023. By application, the market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the market in 2023. In vitro diagnostics implies tests carried out in test tubes and similar equipment and not in the body. In vitro testing can be performed in laboratories, hospitals, or at home. The tests can be carried out on a wide range of tools, from simple handheld devices to complicated laboratory equipment, for the accurate diagnosis of patients. The major clinical applications of liquid biopsy include the detection of cancer. The ease of sampling, acceptance among the masses, and cost-effectiveness and reproducibility of outcomes are the prominent benefits of liquid biopsy-based diagnosis. The ongoing clinical studies for the early detection of cancer are resulting in significant strides in liquid biopsy technologies. While circulating tumor DNA (ctDNA) detection solutions are gaining traction, circulating tumor cells (CTC) and extracellular vesicles (EV) technologies are unlocking their potential for liquid biopsy tests. ctDNA solutions are opening new opportunities for the use of ctDNA in clinical translation to distinct applications across the cancer. Thus, liquid biopsy is increasingly being employed in vitro diagnostic procedures with ongoing technological advancements, which, in turn, fuel the demand for blood collection tubes used in the preparatory stages.

Based on end user, the blood collection tubes for liquid biopsy market is divided into genetic diagnostic labs, R&D centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest blood collection tubes for liquid biopsy market share in 2023.

The blood collection tubes for liquid biopsy market analysis has been carried out by considering the following segments: product, material, application, end user, and geography. Based on product, the market is divided into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. Based on material, the blood collection tubes for liquid biopsy market is divided into glass and plastic. By application, the market is bifurcated into in-vitro diagnostics (IVD) and research. Based on end user, the blood collection tubes for liquid biopsy market is divided into genetic diagnostic labs, R&D centers, conventional diagnostic centers, and others.

The geographic scope of the blood collection tubes for liquid biopsy market report includes the assessment of the market performance in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), South & Central America (Brazil, Argentina, and Rest of South & Central America), and the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com